A. Pèrez

Piel y lípidos, dermatitis atópica y aceites de oliva

V. G. Villarrubia, A. Pèrez, Julián Bayón Planas, 2009 .

Safety and efficacy of oral calcitriol (1, 25 ‐dihydroxyvitamin D3) for the treatment of psoriasis

A. Turner, A. Pèrez, T. Chen, 1996, The British journal of dermatology.

Prevention of postmenopausal bone loss by pulsed estrogen therapy: comparison with transdermal route.

P. Delmas, P. Lopès, C. Ribot, 2004, Maturitas.

Efficacy and safety of topical calcitriol (1,25‐dihydroxyvitamin D3) for the treatment of psoriasis

M. Holick, Tai C. Chen, J. Bhawan, 1996, The British journal of dermatology.

Seasonal Deficiency of Vitamin D in Children: A Potential Target for Osteoporosis‐Preventing Strategies?

J. Riancho, J. González‐Macías, J. Olmos, 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Topical calcitriol (1,25-dihydroxyvitamin D3) treatment of psoriasis: an immunohistological evaluation.

J. Reichrath, T. Chen, M. Holick, 1997, Acta dermato-venereologica.

Induction of vitamin D receptor mRNA expression in psoriatic plaques correlates with clinical response to 1,25-dihydroxyvitamin D3.

T. Chen, M. Holick, G. Heinrich, 1996, The Journal of investigative dermatology.

Pilot study of topical calcitriol (1,25-dihydroxyvitamin D3) for treating psoriasis in children.

T. Chen, M. Holick, A. Turner, 1995, Archives of dermatology.

1,25-Dihydroxyvitamin D3 for the treatment of psoriasis.

M. Holick, A. Pèrez, R. Raab, 1992, Journal of nutritional science and vitaminology.

High fiber diets slow bone turnover in young men but have no effect on efficiency of intestinal calcium absorption.

L. Allen, M. Holick, A. Yergey, 1993, The Journal of nutrition.

Evaluation of the biochemical and hematological profiles of feedlot hair sheep after the supplementation with generic zilpaterol hydrochloride

M. Delgado, G. López-Rincón, A. Pèrez, 2021 .